Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 273

1.

CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.

Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, Nelson BH.

Clin Cancer Res. 2012 Jun 15;18(12):3281-92. doi: 10.1158/1078-0432.CCR-12-0234. Epub 2012 May 2.

2.

Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.

Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, Ng A, Nielsen JS, Sahota R, Tran E, Webb JR, Wong MQ, Wick DA, Wray A, McMurtrie E, Köbel M, Kalloger SE, Gilks CB, Watson PH, Nelson BH.

PLoS One. 2008;3(10):e3409. doi: 10.1371/journal.pone.0003409. Epub 2008 Oct 15.

3.

Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer.

Webb JR, Wick DA, Nielsen JS, Tran E, Milne K, McMurtrie E, Nelson BH.

Gynecol Oncol. 2010 Sep;118(3):228-36. doi: 10.1016/j.ygyno.2010.05.016. Epub 2010 Jun 11.

PMID:
20541243
4.

Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.

Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH.

Clin Cancer Res. 2014 Jan 15;20(2):434-44. doi: 10.1158/1078-0432.CCR-13-1877. Epub 2013 Nov 4.

5.

Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.

Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M.

Cancer. 1994 Aug 15;74(4):1275-82.

6.

M cell pockets of human Peyer's patches are specialized extensions of germinal centers.

Yamanaka T, Straumfors A, Morton H, Fausa O, Brandtzaeg P, Farstad I.

Eur J Immunol. 2001 Jan;31(1):107-17.

7.

Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer.

Santin AD, Bellone S, Palmieri M, Bossini B, Cane' S, Bignotti E, Roman JJ, Cannon MJ, Pecorelli S.

Int J Gynecol Cancer. 2004 Jan-Feb;14(1):64-75.

PMID:
14764031
8.

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.

Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, Old LJ, Odunsi K.

Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80. doi: 10.1073/pnas.1003345107. Epub 2010 Apr 12.

9.

Tumor-infiltrating B cells come into vogue.

Linnebacher M.

World J Gastroenterol. 2013 Jan 7;19(1):8-11. doi: 10.3748/wjg.v19.i1.8.

11.

Margin-infiltrating CD20(+) B cells display an atypical memory phenotype and correlate with favorable prognosis in hepatocellular carcinoma.

Shi JY, Gao Q, Wang ZC, Zhou J, Wang XY, Min ZH, Shi YH, Shi GM, Ding ZB, Ke AW, Dai Z, Qiu SJ, Song K, Fan J.

Clin Cancer Res. 2013 Nov 1;19(21):5994-6005. doi: 10.1158/1078-0432.CCR-12-3497. Epub 2013 Sep 20.

12.

PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.

Webb JR, Milne K, Nelson BH.

Cancer Immunol Res. 2015 Aug;3(8):926-35. doi: 10.1158/2326-6066.CIR-14-0239. Epub 2015 May 8.

13.

A correlation between the expression of CD 8 antigen and specific cytotoxicity of tumor-infiltrating lymphocytes.

Okada Y, Yahata G, Takeuchi S, Seidoh T, Tanaka K.

Jpn J Cancer Res. 1989 Mar;80(3):249-56.

PMID:
2524461
14.

Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.

Wouters MC, Komdeur FL, Workel HH, Klip HG, Plat A, Kooi NM, Wisman GB, Mourits MJ, Arts HJ, Oonk MH, Yigit R, de Jong S, Melief CJ, Hollema H, Duiker EW, Daemen T, de Bruyn M, Nijman HW.

Clin Cancer Res. 2016 Feb 1;22(3):714-24. doi: 10.1158/1078-0432.CCR-15-1617. Epub 2015 Sep 18.

15.

Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.

Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, Weidmann E, Altmannsberger HM, Knuth A, Jäger E.

Cancer Res. 2005 May 1;65(9):3937-41.

16.

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43. Epub 2005 Dec 12.

17.
19.

Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion.

Dadmarz RD, Ordoubadi A, Mixon A, Thompson CO, Barracchini KC, Hijazi YM, Steller MA, Rosenberg SA, Schwartzentruber DJ.

Cancer J Sci Am. 1996 Sep-Oct;2(5):263-72.

PMID:
9166543
20.

Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.

Tomsová M, Melichar B, Sedláková I, Steiner I.

Gynecol Oncol. 2008 Feb;108(2):415-20. Epub 2007 Nov 26.

PMID:
18037158

Supplemental Content

Support Center